Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Growth Officer | November 07, 2023 | November 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date November 07, 2023 · Filed November 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 124,511 |
Reported balance
After 2023-11-07 transaction · row 1
1 source rowRow 1 · 2023-11-07 · Sale · Disposed 382 · Balance 124,511 F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,037 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · derivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,037 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,913 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · derivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,913 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 14,518 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · derivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,518 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,037 | $11.46 | $115,024.02 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,913 | $14.37 | $84,969.81 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 14,518 | $7.48 | $108,594.64 |
DisclosureSEC source: 0001645113-20-000156 · wf-form4_160408850034942.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Balance reflects corrected total to reflect 11,175 shares sold and reported on Form 4 on June 27, 2019 but not deducted from prior totals. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 700 | $86.07 | $60,251.52 |
DisclosureSEC source: 0001645113-20-000135 · wf-form4_159985552642125.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,465 F2 · shares: On September 9, 2020, pursuant to a Rule 10b5-1 adopted by Mr. Shah, Mr. Shah sold 700 shares in multiple trades at prices ranging from $86.04 to $86.14. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 27,621 | $85.39 | $2,358,629.00 |
DisclosureSEC source: 0001645113-20-000135 · wf-form4_159985552642125.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,165 F1 · shares: On September 9, 2020, pursuant to a Rule 10b5-1 adopted by Mr. Shah, Mr. Shah sold 27,621 shares in multiple trades at prices ranging from $85.00 to $85.98. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 4,200 | $85.01 | $357,054.18 |
DisclosureSEC source: 0001645113-20-000124 · wf-form4_159916541528809.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,786 F2 · shares: On September 2, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 4200 shares in multiple trades at prices ranging from $85.00 to $85.02. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2020 Filed Sep 11, 2020 20:13 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,200 | $85.01 | $357,054.18 |
DisclosureSEC source: 0001645113-20-000133 · wf-form4a_159985520224267.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,786 F1 · kind: Form amended to reflect correct code. Original filing incorrectly marked as P. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 3,779 | $0.00 Strike: $84.68 | $0.00 |
DisclosureSEC source: 0001645113-20-000124 · wf-form4_159916541528809.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,779 Underlying: Ordinary Shares · 3,779 shares Expires 2030-08-31 F3 · derivative.exercise_date: Options to buy 3,779 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:37 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 1,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000124 · wf-form4_159916541528809.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,986 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,048 | $76.81 | $157,306.88 |
DisclosureSEC source: 0001645113-20-000116 · wf-form4_159665837256045.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,018 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,669 | $76.41 | $127,521.61 |
DisclosureSEC source: 0001645113-20-000116 · wf-form4_159665837256045.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,066 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,717 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000111 · wf-form4_159649074278641.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717 Underlying: Ordinary Shares · 3,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,717 | $76.17 | $283,123.89 |
DisclosureSEC source: 0001645113-20-000111 · wf-form4_159649074278641.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 20:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 325 | $50.41 | $16,381.63 |
DisclosureSEC source: 0001645113-20-000096 · wf-form4_159423991775624.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,018 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:48 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,149 | $62.20 | $71,467.80 |
DisclosureSEC source: 0001645113-20-000072 · wf-form4_158888450373702.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,693 F1 · security: On March 10, 2020, the reporting person filed a Form 4 that included information labeled "Restricted Share Units" in column 1, table 1. All shares reported in that table should have been with respect to "Ordinary Shares" and all information in such Form 4 and all subsequent Form 4 reports refer to Ordinary Shares only. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,184 | $60.08 | $71,133.54 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,842 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 2,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Underlying: Ordinary Shares · 2,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,333 | $65.80 | $153,511.40 |
DisclosureSEC source: 0001645113-20-000069 · wf-form4_158871072233446.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,500 | $7.48 Strike: $7.48 | $130,900.00 |
DisclosureSEC source: 0001645113-20-000049 · wf-form4_158387163367218.xml · derivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,518 Underlying: Ordinary Shares · 17,500 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 3,245 | $64.27 | $208,556.15 |
DisclosureSEC source: 0001645113-20-000049 · wf-form4_158387163367218.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,693 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 17,500 | $7.48 | $130,900.00 |
DisclosureSEC source: 0001645113-20-000049 · wf-form4_158387163367218.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,906 | $69.53 | $202,065.80 |
DisclosureSEC source: 0001645113-20-000049 · wf-form4_158387163367218.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,438 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on March 5, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 23:58 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 41,690 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-20-000041 · wf-form4_158345269064978.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,690 Underlying: Ordinary Shares · 41,690 shares Expires 2030-03-02 F2 · derivative.exercise_date: Options to buy 41,690 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 23:58 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 21,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000041 · wf-form4_158345269064978.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,344 F1 · shares: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 21:47 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,485 | $72.97 | $108,360.45 |
DisclosureSEC source: 0001645113-20-000037 · wf-form4_158344482249133.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,721 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,601 | $72.22 | $115,616.22 |
DisclosureSEC source: 0001645113-20-000035 · wf-form4_158318776201211.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,206 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,086 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000035 · wf-form4_158318776201211.xml · derivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,086 Underlying: Ordinary Shares · 3,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,086 | $79.45 | $245,182.70 |
DisclosureSEC source: 0001645113-20-000035 · wf-form4_158318776201211.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,500 | $80.22 | $120,328.50 |
DisclosureSEC source: 0001645113-20-000026 · wf-form4_158292608065025.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,721 F4 · price: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 1500 shares in multiple trades at prices ranging from $80.01 to $80.51. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,332 | $79.45 | $344,173.07 |
DisclosureSEC source: 0001645113-20-000026 · wf-form4_158292608065025.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,221 F3 · price: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 4332 shares in multiple trades at prices ranging from $79.00 to $79.99. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,100 | $78.68 | $165,223.80 |
DisclosureSEC source: 0001645113-20-000026 · wf-form4_158292608065025.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,553 F2 · price: On February 26, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 2100 shares in multiple trades at prices ranging from $77.97 to $78.94. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,067 | $81.16 | $411,217.45 |
DisclosureSEC source: 0001645113-20-000026 · wf-form4_158292608065025.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,653 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 12,999 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000015 · wf-form4_158275551073004.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 12,999 | $88.26 | $1,147,291.74 |
DisclosureSEC source: 0001645113-20-000015 · wf-form4_158275551073004.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 4,580 | $7.48 Strike: $7.48 | $34,258.40 |
DisclosureSEC source: 0001628280-19-012619 · wf-form4_157229448764330.xml · derivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,018 Underlying: Ordinary Shares · 4,580 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 4,580 | $7.48 | $34,258.40 |
DisclosureSEC source: 0001628280-19-012619 · wf-form4_157229448764330.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 20:39 UTC | NovoCure Ltd NVCR · Entity 4494 | OtherOrdinary Shares | 13,835 | $97.80 | $1,353,063.00 |
DisclosureSEC source: 0001209191-19-047412 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,141 F1 · kind: Private sale transaction. Read SEC document |
| August 02, 2019 Filed Aug 6, 2019 20:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,813 | $85.23 | $154,521.99 |
DisclosureSEC source: 0001209191-19-044836 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,976 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,905 | $83.20 | $158,501.72 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 3,718 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · derivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,434 Underlying: Ordinary Shares · 3,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to buy Ordinary Shares · Derivative | 5,115 | $0.00 Strike: $34.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · derivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,343 Underlying: Ordinary Shares · 5,115 shares Expires 2028-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,718 | $83.30 | $309,709.40 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,115 | $82.92 | $424,135.80 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,976 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,115 | $34.00 | $173,910.00 |
DisclosureSEC source: 0001209191-19-044234 · doc4.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to buy Ordinary Shares · Derivative | 12,500 | $0.00 Strike: $19.25 | $0.00 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · derivative · entry 8 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Options to buy Ordinary Shares · 12,500 shares Expires 2027-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 100 | $80.06 | $8,006.00 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 7 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,976 F6 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $78.97 to $79.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 19:57 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,857 | $79.41 | $306,288.23 |
DisclosureSEC source: 0001209191-19-043642 · doc4.xml · nonDerivative · entry 6 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,076 F5 · price: On July 26, 2019, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, he sold these shares in multiple trades at prices ranging from $77.94 to $78.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.